Global Antibody Drug Conjugates (ADC) Market Overview:
Global Antibody Drug Conjugates (ADC) Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Antibody Drug Conjugates (ADC) Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Antibody Drug Conjugates (ADC) involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Antibody Drug Conjugates (ADC) Market:
The Antibody Drug Conjugates (ADC) Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Antibody Drug Conjugates (ADC) Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Antibody Drug Conjugates (ADC) Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Antibody Drug Conjugates (ADC) market has been segmented into:
Breast Cancer End-Use
Blood Cancer End-Use
Other End-Uses).
By Application, Antibody Drug Conjugates (ADC) market has been segmented into:
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Antibody Drug Conjugates (ADC) market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Antibody Drug Conjugates (ADC) market.
Top Key Players Covered in Antibody Drug Conjugates (ADC) market are:
ADC Therapeutics SA
Astellas Pharma Inc.
AstraZeneca Plc
Daiichi Sankyo Co. Ltd.
Enzo Biochem Inc.
F. Hoffmann-La Roche AG
Gilead Sciences Inc.
GSK Plc
ImmunoGen Inc.
MabPlex International
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Antibody Drug Conjugates (ADC) Market Type
4.1 Antibody Drug Conjugates (ADC) Market Snapshot and Growth Engine
4.2 Antibody Drug Conjugates (ADC) Market Overview
4.3 Breast Cancer End-Use
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Breast Cancer End-Use: Geographic Segmentation Analysis
4.4 Blood Cancer End-Use
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Blood Cancer End-Use: Geographic Segmentation Analysis
4.5 Other End-Uses).
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Other End-Uses).: Geographic Segmentation Analysis
Chapter 5: Antibody Drug Conjugates (ADC) Market Application
5.1 Antibody Drug Conjugates (ADC) Market Snapshot and Growth Engine
5.2 Antibody Drug Conjugates (ADC) Market Overview
5.3
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 : Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Antibody Drug Conjugates (ADC) Market Share by Manufacturer (2025)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ADC THERAPEUTICS SA; ASTELLAS PHARMA
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 INC.; ASTRAZENECA PLC; DAIICHI SANKYO CO.
6.4 LTD.; ENZO BIOCHEM
6.5 INC.; F. HOFFMANN-LA ROCHE AG; GILEAD SCIENCES
6.6 INC.; GSK PLC; IMMUNOGEN
6.7 INC.; MABPLEX INTERNATIONAL
Chapter 7: Global Antibody Drug Conjugates (ADC) Market By Region
7.1 Overview
7.2. North America Antibody Drug Conjugates (ADC) Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Breast Cancer End-Use
7.2.2.2 Blood Cancer End-Use
7.2.2.3 Other End-Uses).
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Antibody Drug Conjugates (ADC) Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Breast Cancer End-Use
7.3.2.2 Blood Cancer End-Use
7.3.2.3 Other End-Uses).
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Antibody Drug Conjugates (ADC) Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Breast Cancer End-Use
7.4.2.2 Blood Cancer End-Use
7.4.2.3 Other End-Uses).
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Antibody Drug Conjugates (ADC) Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Breast Cancer End-Use
7.5.2.2 Blood Cancer End-Use
7.5.2.3 Other End-Uses).
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Antibody Drug Conjugates (ADC) Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Breast Cancer End-Use
7.6.2.2 Blood Cancer End-Use
7.6.2.3 Other End-Uses).
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Antibody Drug Conjugates (ADC) Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Breast Cancer End-Use
7.7.2.2 Blood Cancer End-Use
7.7.2.3 Other End-Uses).
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Antibody Drug Conjugates (ADC) Scope:
|
Report Data
|
Antibody Drug Conjugates (ADC) Market
|
|
Antibody Drug Conjugates (ADC) Market Size in 2025
|
USD XX million
|
|
Antibody Drug Conjugates (ADC) CAGR 2025 - 2032
|
XX%
|
|
Antibody Drug Conjugates (ADC) Base Year
|
2024
|
|
Antibody Drug Conjugates (ADC) Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., Enzo Biochem Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GSK Plc, ImmunoGen Inc., MabPlex International.
|
|
Key Segments
|
By Type
Breast Cancer End-Use
Blood Cancer End-Use
Other End-Uses).
By Applications
|
